Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Schaberl-Moser Renate |
** = Publikationen gelistet in SCI/SSCI/Pubmed
2021
Originalarbeit (Zeitschrift)
** Gnant, M; Fitzal, F; Rinnerthaler, G; Steger, GG; Greil-Ressler, S; Balic, M; Heck, D; Jakesz, R; Thaler, J; Egle, D; Manfreda, D; Bjelic-Radisic, V; Wieder, U; Singer, CF; Melbinger-Zeinitzer, E; Haslbauer, F; Sevelda, P; Trapl, H; Wette, V; Wimmer, K; Gampenrieder, SP; Bartsch, R; Kacerovsky-Strobl, S; Suppan, C; Brunner, C; Deutschmann, C; Soelkner, L; Fesl, C; Greil, R, , Austrian, Breast, and, Colorectal, Cancer, Study, Group;Austrian, Breast, and, Colorectal, Cancer, Study, Group
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
N Engl J Med. 2021; 385(5):395-405
Doi: 10.1056/NEJMoa2104162
Web of Science
PubMed
FullText
FullText_MUG
** Müller, M; Posch, F; Kiem, D; Barth, D; Horvath, L; Stotz, M; Schaberl-Moser, R; Pichler, M; Greil, R; Jost, PJ; Seeber, A; Amann, A; Schlick, K; Gerger, A; Riedl, JM
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis.
Ther Adv Med Oncol. 2021; 13: 17588359211039930
Doi: 10.1177/17588359211039930
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, DA; Rossmann, CH; Stotz, M; Schaberl-Moser, R; Pichler, M; Stöger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Eur J Cancer. 2021; 151: 3-13.
Doi: 10.1016/j.ejca.2021.03.040
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Abstract (Zeitschrift)
** Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis.
ONCOL RES TREAT. 2020; 43(SUPPL 4):215-215.
[Poster]
Web of Science
** Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis.
WIEN KLIN WOCHENSCHR. Abstracts 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):78-79.-51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA.
[Poster]
Web of Science
** Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
ANN ONCOL. 2020; 31: S942-S942.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2013
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
** Schwarzenbacher, E; Moik, F; Horvath, L; Renneberg, F; Posch, F; Barth, D; Gantschnigg, A; Schaberl-Moser, R; Pichler, M; Stotz, M; Stoger, H; Ay, C; Greil, R; Gerger, A; Djanani, A; Schlick, K; Riedl, J
Incidence, prediction and outcome of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of Gemcitabine/nab-Paclitxel or FOLFIRINOX.
ONCOL RES TREAT. 2020; 43(SUPPL 4):214-214.
[Poster]
Web of Science
** Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM
Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX.
ANN ONCOL. 2020; 31: S949-S950.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK.
Doi: 10.1016/j.annonc.2020.08.2035
[Poster]
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
2019
Originalarbeit (Zeitschrift)
** Moik, F; Riedl, JM; Winder, T; Terbuch, A; Rossmann, CH; Szkandera, J; Bauernhofer, T; Kasparek, AK; Schaberl-Moser, R; Reicher, A; Prinz, F; Pichler, M; Stöger, H; Stotz, M; Gerger, A; Posch, F
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis.
Sci Rep. 2019; 9(1):5548
Doi: 10.1038/s41598-019-42069-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Scheithauer, W; Putora, PM; Grünberger, B; Eisterer, W; Wöll, E; Prager, G; Schaberl-Moser, R; Greil, R; Glatzer, M
Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine.
Therap Adv Gastroenterol. 2019; 12(5):1756284819877635-1756284819877635
Doi: 10.1177/1756284819877635
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2017
Originalarbeit (Zeitschrift)
** Riedl, JM; Posch, F; Bezan, A; Szkandera, J; Smolle, MA; Winder, T; Rossmann, CH; Schaberl-Moser, R; Pichler, M; Stotz, M; Stöger, H; Gerger, A
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.
BMC Cancer. 2017; 17(1):415-415
Doi: 10.1186/s12885-017-3392-4
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Abstract (Zeitschrift)
** Riedl, J; Posch, F; Stotz, M; Bezan, A; Winder, T; Schaberl-Moser, R; Pichler, M; Stoeger, H; Gerger, A
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK.
Doi: 10.1093/annonc/mdw370.107
[Poster]
Web of Science
FullText
FullText_MUG
** Scheithauer, W; Prager, G; Greil, R; Mlineritsch, B; Schaberl-Moser, R; Gerger, A; Langle, F; Viragos-Toth, I; Andel, J; Pichler, A; Pecherstorfer, M; Kretschmer, A; Seebacher, A; Jagdt, B; Eisterer, W; Krippl, P
Secondary resectability rates observed in a multicenter randomized phase II study of modified capecitabine/ irinotecan (mXELIRI) plus bevacizumab (bev) followed by capecitabine/oxaliplatin (XELOX) plus bev or the reverse sequence in patients with metastatic colorectal cancer (mCRC)
ANN ONCOL. 2016; 27: -41st Congress of the European-Society-for-Medical-Oncology (ESMO); OCT 07-11, 2016; Copenhagen, DENMARK.
Doi: 10.1093/annonc/mdw370.41
[Poster]
Web of Science
FullText
FullText_MUG
2015
Originalarbeit (Zeitschrift)
** Stotz, M; Szkandera, J; Stojakovic, T; Seidel, J; Samonigg, H; Kornprat, P; Schaberl-Moser, R; Seggewies, F; Hoefler, G; Gerger, A; Pichler, M
The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer.
Clin Chem Lab Med. 2015; 53(3):499-506
Doi: 10.1515/cclm-2014-0447
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Herzog, S; Pichler, M; Stiegelbauer, V; Stotz, M; Schaberl-Moser, R; Samonigg, H; Asslaber, M; Lax, S; Leitner, G; Renner, W; Lenz, HJ; Berghold, A; Gerger, A
LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.
Pharmacogenomics J. 2015; 15(5):391-396
Doi: 10.1038/tpj.2015.2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2014
Originalarbeit (Zeitschrift)
** Heitzer, E; Artl, M; Filipits, M; Resel, M; Graf, R; Weißenbacher, B; Lax, S; Gnant, M; Wrba, F; Greil, R; Dietze, O; Hofbauer, F; Böhm, G; Höfler, G; Samonigg, H; Schaberl-Moser, R; Balic, M; Dandachi, N
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
Mod Pathol. 2014; 27(6):906-915
Doi: 10.1038/modpathol.2013.204
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Stotz, M; Pichler, M; Absenger, G; Szkandera, J; Arminger, F; Schaberl-Moser, R; Samonigg, H; Stojakovic, T; Gerger, A
The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer.
Br J Cancer. 2014; 110(2):435-440
Doi: 10.1038/bjc.2013.785
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Stotz, M; Szkandera, J; Seidel, J; Stojakovic, T; Samonigg, H; Reitz, D; Gary, T; Kornprat, P; Schaberl-Moser, R; Hoefler, G; Gerger, A; Pichler, M
Evaluation of uric acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients.
PLoS One. 2014; 9(8):e104730-e104730
Doi: 10.1371/journal.pone.0104730
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Pichler, M; Absenger, G; Stotz, M; Arminger, F; Weissmueller, M; Schaberl-Moser, R; Samonigg, H; Kornprat, P; Stojakovic, T; Avian, A; Gerger, A
The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients.
Am J Surg. 2014; 208(2):210-214
Doi: 10.1016/j.amjsurg.2013.10.030
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Stotz, M; Absenger, G; Stojakovic, T; Samonigg, H; Kornprat, P; Schaberl-Moser, R; Alzoughbi, W; Lackner, C; Ress, AL; Seggewies, FS; Gerger, A; Hoefler, G; Pichler, M
Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.
Br J Cancer. 2014; 110(1):183-188
Doi: 10.1038/bjc.2013.701
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2013
Originalarbeit (Zeitschrift)
** Absenger, G; Szkandera, J; Pichler, M; Stotz, M; Arminger, F; Weissmueller, M; Schaberl-Moser, R; Samonigg, H; Stojakovic, T; Gerger, A
A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients.
Br J Cancer. 2013; 109(2):395-400
Doi: 10.1038/bjc.2013.346
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Absenger, G; Szkandera, J; Stotz, M; Postlmayr, U; Pichler, M; Ress, AL; Schaberl-Moser, R; Loibner, H; Samonigg, H; Gerger, A
Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer.
Anticancer Res. 2013; 33(10):4591-4594
Web of Science
PubMed
** Andritsch, E; Stöger, H; Bauernhofer, T; Andritsch, H; Kasparek, AK; Schaberl-Moser, R; Ploner, F; Samonigg, H
The ethics of space, design and color in an oncology ward.
Palliat Support Care. 2013; 11(3):215-221
Doi: 10.1017/S1478951512000077
Web of Science
PubMed
FullText
FullText_MUG
** Eisner, F; Schaberl-Moser, R; Gerger, A; Samonigg, H; Pichler, M
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Onkologie. 2013; 36(6):368-370
Doi: 10.1159/000351252
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
** Szkandera, J; Stotz, M; Eisner, F; Absenger, G; Stojakovic, T; Samonigg, H; Kornprat, P; Schaberl-Moser, R; Alzoughbi, W; Ress, AL; Seggewies, FS; Gerger, A; Hoefler, G; Pichler, M
External validation of the derived neutrophil to lymphocyte ratio as a prognostic marker on a large cohort of pancreatic cancer patients.
PLoS One. 2013; 8(11):e78225-e78225
Doi: 10.1371/journal.pone.0078225
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2012
Abstract (Zeitschrift)
** Heitzer, E; Marija, B; Resel, M; Graf, R; Weissenbacher, B; Schaberl-Moser, R; Dandachi, N;
IDENTIFICATION OF PROGNOSTIC METHYLATION MARKERS IN PATIENTS WITH EARLY STAGE COLORECTAL CANCER.
ANN ONCOL. 2012; 23: 87-87.-14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO); JUN 27-30, 2012; Barcelona, SPAIN.
[Poster]
Web of Science
2011
Originalarbeit (Zeitschrift)
** Ofner, D; Devries, AF; Schaberl-Moser, R; Greil, R; Rabl, H; Tschmelitsch, J; Zitt, M; Kapp, KS; Fastner, G; Keil, F; Eisterer, W; Jäger, R; Offner, F; Gnant, M; Thaler, J; TAKO 05/ABCSG R-02 Trial Investigators
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Strahlenther Onkol. 2011; 187(2):100-107
Doi: 10.1007/s00066-010-2182-6
Web of Science
PubMed
FullText
FullText_MUG
** Resch, G; Schaberl-Moser, R; Kier, P; Kopetzky, G; Scheithauer, W; Sliwa, T; Greil, R; Nösslinger, T; Mayrbäurl, B; Thaler, J
Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
Ann Oncol. 2011; 22(2): 486-487.
Doi: 10.1093/annonc/mdq744
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Thalhammer, M; Kohek, P; Suppan, C; Lackner, K; Schaberl-Moser, R; Schoellnast, H; Werkgartner, G; Mischinger, H
Benefit of chemotherapy in patients with ductal adenocarcinoma of the pancreas with vascular infiltration.
ANN ONCOL. 2011; 22: v61-v61.-World Congress on Gastrointestinal Cancer (WCGIC); JUN 22-25, 2011; Barcelona, SPAIN.
[Poster]
Web of Science
2009
Originalarbeit (Zeitschrift)
** Mlineritsch, B; Schabel-Moser, R; Andel, J; Fridrik, M; Moik, M; Mayer, P; Russ, G; Rass, C; Greil, R; Arbeitsgemeinschaft medikamentöse Tumortherapie Study Group
Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Onkologie. 2009; 32(1-2):18-24
Doi: 10.1159/000180915
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Komek, G; Schueller, J; Schaberl-Moser, R; Keil, F; Andel, J; Renner, F; Eisterer, W; Balcke, P; Scheithauer, W
LIMITED TREATMENT DURATION & RE-INDUCTION OF THE SAME REGIMEN UPON PROGRESSION VERSUS TREATMENT UNTIL PROGRESSION WITH XELOX plus BEVACIZUMAB IN PATIENTS WITH ADVANCED COLORECTAL CANCER
ANN ONCOL. 2009; 20: 62-62.
[Poster]
Web of Science
2008
Abstract (Zeitschrift)
** Douillard, J; Rolski, J; Barone, C; Schaberl-Moser, R; Eggleton, SP
CAN UFT REPLACE INFUSIONAL 5-FU IN COMBINATION THERAPY FOR METASTATIC COLORECTAL CANCER (MCRC)? PRELIMINARY RESULTS OF THE RANDOMISED FUTURE'' STUDY
ANN ONCOL. 2008; 19: 134-134.-33rd European-Society-for-Medical-Oncology Congress; SEP 12-16, 2008; Stockholm, SWEDEN.
[Poster]
Web of Science
** Rolski, J; Barone, C; Schaberl-Moser, R; Eggleton, S; Douillard, J
Randomized trial of either UFT or infusional 5-FU in combination with Erbitux, oxaliplatin and folinic acid in first-line treatment of metastatic colorectal cancer
ANN ONCOL. 2008; 19: 27-28.
Web of Science
** Scheithauer, W; Kornek, G; Aigner, K; Schaberl-Moser, R; Keil, F; Andel, J; Renner, F; Eisterer, W; Balcke, P; Schuller, J
LIMITED TREATMENT DURATION AND RE-INDUCTION WITH THE SAME REGIMEN ON PROGRESSION VS TREATMENT UNTIL PROGRESSION WITH BIWEEKLY CAPECITABINE plus OXALIPLATIN +/- BEVACIZUMAB IN PATIENTS (PTS) WITH ADVANCED COLORECTAL CANCER (CRC): A RANDOMISED PHASE II STUDY
ANN ONCOL. 2008; 19: 169-169.-33rd European-Society-for-Medical-Oncology Congress; SEP 12-16, 2008; Stockholm, SWEDEN.
[Poster]
Web of Science
2007
Originalarbeit (Zeitschrift)
** Schippinger, W; Samonigg, H; Schaberl-Moser, R; Greil, R; Thödtmann, R; Tschmelitsch, J; Jagoditsch, M; Steger, GG; Jakesz, R; Herbst, F; Hofbauer, F; Rabl, H; Wohlmuth, P; Gnant, M; Thaler, J; Austrian Breast and Colorectal Cancer Study Group
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
BRIT J CANCER. 2007; 97(8): 1021-1027.
Doi: 10.1038/sj.bjc.6604011
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
2005
Originalarbeit (Zeitschrift)
** Schippinger, W; Jagoditsch, M; Sorré, C; Gnant, M; Steger, G; Hausmaninger, H; Mlineritsch, B; Schaberl-Moser, R; Mischinger, HJ; Hofbauer, F; Holzberger, P; Mittlböck, M; Jakesz, R; Austrian Breast and Colorectal Cancer Study Group
A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
BRIT J CANCER. 2005; 92(9): 1655-1662.
Doi: 10.1038/sj.bjc.6602555
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2002
Originalarbeit (Zeitschrift)
** Regitnig, P; Moser, R; Thalhammer, M; Luschin-Ebengreuth, G; Ploner, F; Papadi, H; Tsybrovskyy, O; Lax, SF
Microsatellite analysis of breast carcinoma and corresponding local recurrences.
J Pathol. 2002; 198(2):190-197
Doi: 10.1002/path.1193
Web of Science
PubMed
FullText
FullText_MUG
1999
Originalarbeit (Zeitschrift)
** Hausmaninger, H; Moser, R; Samonigg, H; Mlineritsch, B; Schmidt, H; Pecherstorfer, M; Fridrik, M; Kopf, C; Nitsche, D; Kaider, A; Ludwig, H
Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
Eur J Cancer. 1999; 35(3):380-385
Doi: 10.1016%2FS0959-8049%2898%2900397-9
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
1998
Originalarbeit (Zeitschrift)
** Lackner, C; Moser, R; Bauernhofer, T; Wilders-Truschnig, M; Samonigg, H; Berghold, A; Zatloukal, K
Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis.
Breast Cancer Res Treat. 1998; 47(1):29-40
Doi: 10.1023%2FA%3A1005913514376
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
1995
Originalarbeit (Zeitschrift)
** Moser, R; Hausmaninger, H; Ludwig, H; Fridrik, M; Schmidt, H; Mlineritsch, B; Pecherstorfer, M; Michlmayr, G; Kopf, C; Samonigg, H
5-Fluorouracil and Folinic Acid with or Without Alpha-2C Interferon in the Treatment of Metastatic Colorectal-Cancer - Preliminary-Results of a Multicenter Prospective Randomized Phase-III Trial
ONKOLOGIE 1995 18: 131-135.
Doi: 10.1159/000218573
Web of Science
FullText
FullText_MUG
1994
Originalarbeit (Zeitschrift)
** Stöger, H; Bauernhofer, T; Kasparek, AK; Schmid, M; Moser, R; Ploner, F; Derstvenscheg, E; Kuss, I; Wilders-Truschnig, M; Steindorfer, P
Weekly 5-fluorouracil and high-dose folinic acid in combination with epidoxorubicin as first-line therapy in advanced breast cancer: a phase II study.
Cancer Chemother Pharmacol. 1994; 34(1):75-78
Doi: 10.1007/BF00686116
Web of Science
PubMed
FullText
FullText_MUG
** Stöger, H; Bauernhofer, T; Moser, R; Derstvenscheg, E; Schmid, M; Ploner, F; Pakisch, B; Wilders-Truschnig, M; Haas, J; Steindorfer, P
Breast cancer in the man: a report of 30 patients].
Wien Klin Wochenschr. 1994; 106(18):575-580
Web of Science
PubMed
Google Scholar
** Stöger, H; Bauernhofer, T; Schmid, M; Ploner, F; Moser, R; Derstvenscheg, E; Steindorfer, P; Wilders-Truschnig, M; Kuss, I; Samonigg, H
A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Cancer Chemother Pharmacol. 1994; 35(2):174-178
Doi: 10.1007/BF00686643
Web of Science
PubMed
FullText
FullText_MUG
** Stöger, H; Schmid, M; Bauernhofer, T; Moser, R; Ploner, F; Derstvenscheg, E; Kasparek, AK; Kuss, I; Wilders-Truschnig, M; Lackner, C
A phase II trial of weekly high-dose folinic acid and 5-fluorouracil in combination with epirubicin as salvage chemotherapy in advanced breast cancer.
Oncology. 1994; 51(6):518-522
Doi: 10.1159/000227397
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar